


Important Information about Privigen® NZ



From the 15th August 2023, PRIVIGEN® NZ will be the product of choice for all new requests for long-term intravenous immunoglobulin (IVIg) treatment. A phased transition of PRIVIGEN® NZ, for patients currently on INTRAGAM® P, will commence from the 25th July 2023.

NZBS will continue to supplement Blood Bank inventory with PRIVIGEN®, a commercial IVIg, produced from paid European and North American plasma donors. PRIVIGEN® will be utilised for patients receiving short term (3 months or less) or intermittent IVIg treatment. Primarily, PRIVIGEN® will be held at the six NZBS Blood Banks, to streamline other Blood Banks inventory to one preparation of Privigen only.

PRIVIGEN® and PRIVIGEN® NZ are different products.



Please ensure the correct approved product is prescribed, requested and selected for issue.

If you suspect a patient has been incorrectly infused with PRIVIGEN® instead of PRIVIGEN® NZ, or vice versa, this is a medication error. Please follow your normal process for investigating and reporting.

Report to New Zealand Blood Service at adverse.reaction@nzblood.co.nz

Reporting forms can be obtained from your supplying Blood Bank.